NGNE
Neurogene IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$336.56M
P/E Ratio
—
EPS
$-4.24
Beta
1.89
52W High
$37.27
52W Low
$8.99
50-Day MA
$19.77
200-Day MA
$21.29
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Neurogene Inc
Neurogene Inc. is a pioneering biotechnology firm specializing in the development of groundbreaking gene therapies aimed at addressing rare neurological disorders. With a focus on leveraging cutting-edge genetic medicine technologies, the company is committed to creating transformative treatments that meet significant unmet medical needs. Neurogene's robust pipeline of proprietary programs, coupled with its experienced leadership team, emphasizes its dedication to advancing the field of genetic therapies. As the company navigates its clinical development phases, it is well-positioned to enhance the quality of life for patients and families affected by genetic diseases.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-74.89M |
| EBITDA | $-100.12M |
| Operating Margin | 0.00% |
| Return on Equity | -31.40% |
| Return on Assets | -20.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $17.10 |
| Price-to-Book | 1.22 |
| Price-to-Sales (TTM) | 583.60 |
| EV/Revenue | 480.94 |
| EV/EBITDA | -8.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $15.57M |
| Float | $5.11M |
| % Insiders | 8.78% |
| % Institutions | 108.75% |
Analyst Ratings
Consensus ($77.67 target)
8
BuyData last updated: 4/9/2026